Over the past decade, the number of clinical trials using a biosimilar treatment has been on the rise.

GlobalData extracted all biosimilar drug trials up to 21 December 2018 and then broke them down by the top 10 drugs in clinical trials.

Top 10 drugs in biosimilar trials

The number one drug in biosimilar clinical trials by count is adalimumab biosimilar, referencing the branded biologic Humira. The drug is a tumour necrosis factor (TNF) blocker used for the treatment of a variety of autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and plaque psoriasis.

The third highest biosimilar by trial count, shown in Figure 1, is infliximab biosimilar for the treatment of the same indications. Etanercept biosimilar, coming in at sixth position, is also a TNF blocker used for autoimmune indications.

The second drug on the list is rituximab biosimilar, a treatment for oncology indications such as non-Hodgkin’s lymphoma. This drug is also in clinical trials for autoimmune diseases, much like the three biosimilars discussed above. Bevacizumab biosimilar and trastuzumab biosimilar are both aimed at oncology indications specifically, such as certain colorectal, lung, brain, kidney, and cervical cancers, and breast cancer.

However, if you count filgrastim and the pegylated version, pegfilgrastim, together in Figure 1, these two drugs would have the highest clinical trial count by far. They are treatments for neutropenia, a haematological disorder, which was the third highest therapy area by count. Filgrastim is a recombinant-DNA form of naturally occurring granulocyte colony-stimulating factor (G-CSF). It works by stimulating the body to increase neutrophil production. The two drugs at the bottom of the list, epoetin alfa and darbepoetin alfa, are also treatments for a haematological disorder, namely anaemia, which was the third highest indication.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Figure 1: Top 10 drugs in biosimilar clinical trials

Source: GlobalData